Safety, Efficacy and Acute Angiographic Outcome of the New Everolimus Eluting Stent with Correlation to Short-Term Clinical Follow-up in Patient with Acute Coronary Syndrome

Abstract Background: Drug-eluting stents are used in 80%. To 90% of revascularization procedures in the United States. Everolimus embedded in a durable polymer on a cobalt chromium Stent has shown superiority compared with Bare Metal Stents (BMS), and paclitaxel eluting stent for reduction of both late loss and binary restenosis. Aim of Study: To study the safety, efficacy and acute angiographic outcome of the new Everolimus Eluting Stent in correlation with short-term clinical follow-up in patient with Acute Coronary Syndrome (ACS). Patients and Methods: A prospective study in which ninety-five patients with (ACS), Scheduled for PCI in the cardiac catheterization laboratory in Cairo University Hospitals or NHI, using Everolimus DES, were enrolled from Jan. 2009 to June 2009. Their clinical, angiographic, interventional and follow-up data were collected and analyzed. Results: Acute success was achieved in all the cases with no device failure, after six month of follow-up, patients (94.5%) had expressed no events or chest pain, 1 patient had stable angina and refused to redo the coronary angiography, 3 patients had redo the coronary angiography due to recurrent chest pain (two of them had redo PCI in remote vessel and the other had no significant lesion), and 1 patient died because of retroperitoneal hematoma. Conclusion: The everolimus eluting stent are a safe type of drug eluting stent in clinical Practice with favorable short term outcomes in patients with acute coronary syndromes.